However, among the initial responders to such treatments, approximately 70% of them eventually develop resistance, with 30% displaying inherent resistance to VEGF-TKIs [2], and has been intricately linked with high tumor heterogeneity and the tumor microenvironment (TME) [3]. The gene discussed is VEGFA; the disease is neoplasm.